Lamisil Once (Terbinafine)

Terbinafine blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. The resulting buildup of squalene and loss of ergosterol compromise membrane integrity, leading to fungal cell death and clearance of the infection.

The specific dosing regimen for Lamisil Once is determined by the prescribing healthcare professional based on the infection type, severity, patient age and skin condition. Patients should follow the instructions provided on the prescription label and by their clinician.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil Once.

To request Lamisil Once, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil Once (terbinafine) belongs to the allylamine class, which directly inhibits squalene epoxidase, offering a rapid fungicidal effect. Compared with azole antifungals that target lanosterol 14α‑demethylase, terbinafine often requires a shorter treatment duration for superficial infections and has a distinct safety profile.

Lamisil Once should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

The cream or solution is applied thinly to the affected skin area once daily, or as directed by the prescriber, after washing and drying the skin. The treated area should be covered with a clean dressing if recommended, and the medication should be used for the full course prescribed.

While most reactions are mild, serious risks include severe allergic responses such as anaphylaxis, extensive contact dermatitis, blistering, or rare conditions like Stevens‑Johnson syndrome. Any signs of widespread rash, swelling, or difficulty breathing require immediate medical attention.

Individuals with known hypersensitivity to terbinafine or any component of the formulation should avoid using Lamisil Once. It is also contraindicated on severely damaged or inflamed skin, and patients should consult a clinician before use if they have liver disease, are pregnant, or are breastfeeding.